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An understanding of the pathogenesis and pathophysiology of Lyme disease is key
to the ultimate care of patients with Lyme disease. To better understand the various
mechanisms underlying the infection caused by Borrelia burgdorferi, the Pathogenesis
and Pathophysiology of Lyme Disease Subcommittee was formed to review what is
currently known about the pathogenesis and pathophysiology of Lyme disease, from
its inception, but also especially about its ability to persist in the host. To that end, the
authors of this report were assembled to update our knowledge about the infectious
process, identify the gaps that exist in our understanding of the process, and provide
recommendations as to how to best approach solutions that could lead to a better means
to manage patients with persistent Lyme disease.
Keywords: Lyme disease, pathogenesis, pathophysiology, health and human services, tick borne disease working
group
INTRODUCTION
This Report focuses on the pathogenesis and pathophysiology of Lyme disease. There are other
HHS TBDWG subcommittee reports that instead focus on clinical aspects of Lyme disease,
and other tick-borne diseases, including issues related to the treatment of these diseases, that
are posted on the HHS TBDWG website. Here we summarize presentations by subcommittee
members, as well as those of several other, invited investigators. It is recognized that there are
many other important contributions by notable investigators in the area of pathogenesis and
pathophysiology of Lyme disease and other tick-borne diseases that have not been included here,
due to time-limitations for the subcommittee.
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BACKGROUND
An understanding of the pathogenesis and pathophysiology
of Lyme disease is key to the ultimate care of patients with
Lyme disease. To better understand the various mechanisms
underlying the infection caused by Borrelia burgdorferi,
the Pathogenesis and Pathophysiology of Lyme Disease
Subcommittee was formed to review what is currently known
about the pathogenesis and pathophysiology of Lyme disease,
from its inception, but also especially about B. burgdorferi’s ability
to persist in the host. To that end, the authors of this report were
assembled to update our knowledge about the infectious process,
identify the gaps that exist in our understanding of the process
(Figure 1), and provide recommendations as to how to best
approach solutions that could lead to a better means to manage
patients with persistent Lyme disease.
It has been established that the major causative organism
of Lyme disease, B. burgdorferi, can persist in a number of
animal models and human case studies following infection
and treatment with a “standard” course of antibiotics (1–4).
However, it is still unclear whether human patients with
ongoing symptoms associated with Lyme disease continue to
have an active infection following completion of what seems
as appropriate antibiotic therapy. Thus, the extent to which
unresolved infection, incomplete clearance of borrelial antigens,
and/or autoimmunity contribute to persistent Lyme disease
symptoms is unclear (5, 6).
To better understand the pathogenesis and pathophysiology of
Lyme disease, the progression of B. burgdorferi from its reservoir
in the Ixodes tick to transmission into the vertebrate host and
to its localization and persistence in neural and other tissues
are key steps toward finding means to resolve the infection.
The following are descriptions of some of what is known about
these various factors of the pathogenesis and pathophysiology of
Lyme disease.
Transmission and Dissemination of
B. burgdorferi in the Vertebrate Host
In the midgut of a molted, unfed tick, B. burgdorferi’s survival in
a dormant state requires only a small amount of energy, because
little to no bacterial replication occurs (7). Outer surface proteins
(Osps) facilitate the pathogen’s adhesion to midgut tissue. A tick’s
ingestion of blood provides B. burgdorferiwith copious nutrition,
resulting in rapid bacterial replication. In turn, B. burgdorferi
stops producing tick-specific adhesins and starts producingOspC
and other factors required for transmission of the pathogen to
vertebrates (8). After initiation of a blood meal, the infected tick’s
midgut swells, and the junctions between midgut cells become
thinner. Borrelia burgdorferi then penetrates those junctions and
enters the tick’s salivary glands and salivary ducts, thereby setting
the stage for its transmission to a vertebrate via tick bite. Upon
injection into the vertebrate host, the bacteria adhere to tissues
and replicate at the bite site (8, 9). Dissemination of B. burgdorferi
throughout the vertebrate host involves migration through
tissues, as well as transport via the bloodstream, resulting in a
brief period of bacteremia.
There are a number of questions meriting additional
investigation, including processes occurring inside the tick, as
well as the processes of initial entry and dissemination, such as
the following:
• How does B. burgdorferi sense its location in the tick-
mammal infectious cycle, then use that information to regulate
production of its proteins?
• What are the signals that “tell” B. burgdorferi that a vector tick
is feeding and that it is time to transmit out of the tick?
• How does B. burgdorferi get into the tick’s salivary glands and
salivary ducts?
• How does B. burgdorferi control production of host-
specific proteins?
• When bacteria adhere to host tissues at the tick’s bite
site and then replicate, to what kinds of tissues do they
adhere? What types of proteins is B. burgdorferi making to
facilitate adherence?
• Upon infection of a human, how does B. burgdorferi spread? It
is known to migrate through skin and other solid tissue, but
does it go through the lymphatic system or attach to nerve
endings? Does it localize in sensory ganglia? What is the role
of adhesins in dissemination throughout the vertebrate host?
Are there particular host tissues that attract B. burgdorferi?
Gene Regulation of B. burgdorferi During
Colonization, Dissemination, and
Tissue-Specific Infection in Mice
Borrelia burgdorferi can sense whether it is located in a tick
or mammal and adapt its response to environmental signals,
such as temperature, pH, oxygen levels, carbon dioxide levels,
nutrient availability, and reactive oxygen species (7). The rate of
bacterial replication has effects on expression levels of numerous
infection-associated genes and proteins. Carbon dioxide is
important in determining the virulence of B. burgdorferi in
mice. Borrelial oxidative stress regulator plays a pivotal role in
establishing mammalian infection. B. burgdorferi can grow and
survive without iron; genes generate an oxidative stress response
that is involved in the transport of manganese and other metals
within B. burgdorferi-infected mice. The use of bioluminescent
borrelia as a tool for studies in mice allows visualization of
the kinetics of infection with different strains of the pathogen
and enables real-time evaluation of gene expression in the skin,
heart, and joints of a mammal infected with B. burgdorferi.
Notably, localized infection with B. burgdorferi becomes more
difficult to detect as the pathogen disseminates throughout the
mouse. An important gap in knowledge is that it is yet to
be determined which genes are required for dissemination of
B. burgdorferi and its colonization of tissues during later stages of
infection (10).
Role of the Immune System in Response to
B. burgdorferi Infection
Borrelia burgdorferi establishes persistent and non-resolving
infections in fully immunocompetent mice, strongly suggesting
that the bacteria have developed multiple and likely complex
immune evasion strategies (9, 11). Both innate and adaptive
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FIGURE 1 | Overview of the gaps in knowledge defined by the working group as areas in need of further research (Created by Biorender.com).
immune responses control B. burgdorferi in these hosts
[reviewed in (12)]. These species rarely, and only transiently,
develop clinical manifestations of disease, without an obvious
correlation between the tissue-loads of B. burgdorferi and clinical
manifestations, except in severely immunocompromised mice,
for example those that lack T and B cells (SCID mice), or the
ability to activate innate immune effectors because of deletions
in the toll-like receptor (TLR) 2 or TLR adaptor protein
MyD88 (13–15). MyD88-mediated innate immune responses
appear to be particularly critical during earliest stages during
the establishment of infection (16). Immunoglobulin (Ig) G
but not IgM antibodies control B. burgdorferi tissue loads, but
cannot clear the infection, even when the antibodies are able
to passively protect from infection of a new host. IgG acts at
least in part through complement-mediated opsonization of the
bacteria for subsequent update by macrophage and granulocytes.
Data suggest that B. burgdorferi suppresses effective innate and
adaptive immunity (9, 11); therefore, the immune system is key
to understanding persistence of Lyme disease.
B cell responses in these reservoir species are characterized
by a lack of continued antibody affinity maturation and the
development of long-lived responses due to the rapid collapse
of germinal centers. Borrelia burgdorferi infection appears
to suppress the adaptive immune response, as indicated by
the reduced immune response to influenza vaccine in mice
infected with B. burgdorferi (17). Ongoing work suggests that
B. burgdorferi also prevents CD4T cells from mounting an
effective immune response to infection, potentially dysregulating
effector immune responses in tissues and failing to suppress
persistent infection of the host. Data were presented to support
the hypothesis that B. burgdorferi suppresses and subverts
adaptive humoral and cellular immunity to itself and to
other antigens. Identifying host immune targets of Borrelia-
mediated immune suppression might result in the development
of approaches that enhance host immunity to this pathogen in a
manner similar to strategies that are currently being explored in
anti-tumor immunity.
Notably, mice, as reservoir hosts, never clear B. burgdorferi
infection without antibiotic treatment; humans and non-human
primates appear to harbor low-level, persistent B. burgdorferi
infection as well (18–20). Persistence appears to be a function
of active immune suppression and immune evasion tactics.
An assay that was developed to detect antibody responses to
five antigens of B. burgdorferi infection following antibiotic
treatment (21) showed that most rhesus macaques infected with
B. burgdorferi generated responses to most of the antigens, but
two showed no specific antibody responses to these antigens (22).
In one study in humans, patients who returned to health after
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antibiotic treatment generated the strongest antibody response
(23), reflected by the percentage of plasmablasts that circulated
in the blood (24), while those with persisting symptoms
had weak responses to antigens or had an anti-oligopeptide
permease A2 antibody titer that did not decline. The reasons
why some patients develop a good antibody response remain
to be determined but might be attributed to host immune
factor differences or to differences in the infecting strains of
B. burgdorferi.
Further studies of immune function in non-human
primates previously vaccinated with B. burgdorferi found
that IgM-producing cells were more frequent and persistent
in B. burgdorferi-infected primates, results similar to those
observed in human patients with persistent Lyme disease as
well as in mice. Memory B cells and plasmablasts were reduced
in B. burgdorferi-infected, unvaccinated macaques compared
with vaccinated macaques; whereas CD4 T-cell memory
populations appeared similar among groups, activation of T
cells was somewhat dampened in the B. burgdorferi-infected
primates. Areas for future research include determining how
long B. burgdorferi-induced immune suppression lasts and the
impact of persistent infection on effectiveness of vaccines.
Chemotaxis, Motility, and Immune Evasion
as Key Factors in B. burgdorferi
Spirochete Persistence
Most spirochetes use flagellin proteins as “motors,” with which
they move back and forth. This movement can be tracked
in real time in mice with the use of multiphoton/confocal
microscopy and fluorescently labeled B. burgdorferi. Ongoing
imaging analysis revealed that the number of spirochetes peaked
around 7–10 days after infection (12). This peak was followed
by a dramatic drop in spirochete numbers, where they persisted
for the duration of the experiment. Spirochetes often tend to
reside in the dermis. Of the various resident immune response
cells, Langerhans cells were not as effective as macrophages, or
other dendritic cells or neutrophils in phagocytosing the bacteria,
as spirochetes move up to 80 times faster than any of these
immune response cells (12). Neutrophils responded the fastest,
but after a certain point, they stop responding, leaving a number
of viable spirochetes. There remains a gap in the understanding
of the signals involved in this apparent suppression of
neutrophil responses. Interleukin 10, the most well-characterized
and immunosuppressive cytokine known, is induced early by
B. burgdorferi to control the innate immune response (25).
The innate immune response is important for controlling
early infection, independent of the presence of T and B cells.
B. burgdorferi stimulates several pattern recognition receptors
of the innate immune response, inducing pro-inflammatory
cytokines (26). Evasion of the innate immune response is
accomplished also by multiple complement-binding proteins
expressed by B. burgdorferi (27), dampening the initial response,
as well as IgG-mediated effort functions. Greater understanding
is still needed regarding the different roles of the innate and
adaptive arms of the immune system in regulating immunity to
the spirochetes.
Role of CD47 and the Immune Response to
B. burgdorferi
Up-regulation of CD47, a relatively conserved “marker of
self,” is a newly discovered mechanism of immune evasion by
B. burgdorferi. When CD47 binds to signal regulatory protein
alpha (SIRP-alpha), there is an inhibition of phagocytosis of those
cells, by macrophages. Anti-CD47 antibodies are currently under
evaluation in clinical trials for cancer treatment (28, 29). It is
hypothesized that B. burgdorferi (among other pathogens) can
mimic CD47 and thus prevent macrophages from destroying
Borrelia via phagocytosis (30). Imaging studies of the immune
response to B. burgdorferi shows that macrophages can send
out a “lasso” that wraps around B. burgdorferi spirochetes and
draws them into the macrophage, usually the first step in the
process of phagocytosis. In a few cases, the spirochetes reside
in the macrophage but never appear to reach the lysosome,
which is where bacterial destruction usually occurs. In donor
sera, the addition of the SIRP-alpha binding domains of its
receptor CV1G4 in vitro can result in increased phagocytosis,
presumably by blocking serum-derived SIRP-alpha to CD47-
like molecules on the spirochete (31). To understand why the
response is more efficient in some settings, the genetic sequences
of CD47 and SIRP-alpha were studied showing that SIRP-alpha
is highly polymorphic (31). While a number of polymorphisms
of CD47 do exist, they are infrequent in humans. Evolutionarily,
there has been long-term balancing selection, which ensures that
proteins that are vital to the immune response are maintained
with maximum diversity, perhaps because the pathogens see
some types of SIRP-alpha as beneficial to them. By using mass
spectrometry and CV1G4 as a binding partner, a Borrelia protein
was identified as a CD47-like anti-phagocytic signal. In the
absence of this protein, macrophages were more effective in
clearing cells. Whether B. burgdorferi can survive by inhibiting
phagolysosome fusion, as is the case with a number of other
known persistent pathogens (32), is currently unknown.
VlsE Protein-Mediated Immune Evasion
VlsE is a surface-expressed protein able to undergo extensive
antigenic variation (33–35). Its expression and ability to undergo
antigenic variation is required for B. burgdorferi survival and
persistence in the presence of a host humoral antibody response
targeted against VlsE (36), but also against other surface proteins.
A longstanding question has been how B. burgdorferi immune
escape is accomplished through sequence variation of this
single lipoprotein can accomplish immune escape, despite the
presence of a substantial number of additional antigens residing
on the bacterial surface. A function for VlsE other than its
antigenic variation, and thus constant evasion from the humoral
antibody response, is not currently known to exist. Although
other forms of immune evasion have been proposed, antigenic
variation occurs even in antibody-deficient severe combined
immunodeficient mice. Among the several models that have been
suggested, one scenario proposes that VlsE may act as a shield to
obscure the epitopes of other surface antigens (37).
One example of this is the immunogenic Arp protein of
B. burgdorferi, which is responsible for joint inflammation during
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infection. Despite Arp eliciting a strong humoral response,
antibodies fail to clear the infection. Subsequent studies revealed
that VlsE seems to prevent binding of Arp-specific antibodies
to the surface of B. burgdorferi, thereby providing a possible
explanation for the failure of Arp antisera to clear the infection.
However, other surface-expressed proteins of B. burgdorferi
do not seem to be blocked by expression of VlsE, and Arp
remains highly immunogenic. Thus, VlsE does not appear to be
a universal protector of all B. burgdorferi cell surface antigens.
Therefore, other, as-of-yet-unknown mechanisms of immune
evasion from antibody-mediated Borrelia clearance may exist.
Evidence That Persisting B. burgdorferi
Are Metabolically Active and Induce Host
Gene Expressions
Evidence now exists, from the results of experiments in
both murine and non-human primate models, that persisting
B. burgdorferi can be metabolically active, expressing certain
bacterial genes and inducing gene expression changes in the
infected host, despite being non-culturable following antibiotic
treatment (22, 37–39). In one model, the spirochetes localized to
the dura mater of the brain, associated with large-scale changes in
gene expression of pro-inflammatory cytokines and chemokines
(40, 41). Although there was no evidence of direct infection of
the brain itself in this model, certain brain tissues expressed
genes related to interferon signaling pathways. Gene expression
of other brain functions—for example, glutamate receptors—
have not yet been studied. These results, then, provide support
for the hypothesis that it is persisting infection that is the cause of
persisting symptoms in patients with persistent Lyme disease.
One of the greatest challenges is to actually find means
to intervene in the infectious process, especially if no specific
markers can be found because of low infectious load or
if organisms are in locations other than blood, urine, or
cerebrospinal fluid normally used for diagnosis of Lyme disease.
Whether different antibiotic regimens can be found to eliminate
the persistent state is another challenge that it is hoped can be
met with additional targeted research.
Role of B. burgdorferi in the Pathogenesis
and Persistence of Lyme Arthritis
Borrelia burgdorferi peptidoglycan, the primary component
of the bacterial cell wall, has a unique composition and
plays an important role in bacterial physiology and host
immune responses. Borrelia burgdorferi lack the molecular
machinery required for recycling of peptidoglycan during
cell replication, and the bacteria shed copious amounts of
peptidoglycan fragments (42). These fragments are recognized
by a host pathogen recognition receptor, NOD2, and cells
stimulated with peptidoglycan fragments produce high levels
of pro-inflammatory cytokines. Synovial fluid from some
human patients with Lyme arthritis, many of whom had
received 1–3 months of antibiotic therapy, had high levels
of detectible peptidoglycan, as well as anti-peptidoglycan
antibodies, despite a lack of any evidence of ongoing infection
after antibiotic therapy (42). Thus, it appears that B. burgdorferi
peptidoglycan might be a persistent antigen in Lyme arthritis
(12). Ongoing research is being conducted to determine whether
B. burgdorferi peptidoglycan plays a role in the pathogenesis
and pathophysiology of neuroborreliosis or of persistent Lyme
disease other than previously treated Lyme arthritis.
Approximately 60% of untreated individuals with Lyme
disease in the United States develop Lyme arthritis. Although
most patients with Lyme arthritis respond favorably to 1–
3 months of antibiotic therapy, 10–20% of patients have
persistent arthritis after treatment (43). A number of genetic and
environmental factors contribute to persistent Lyme arthritis,
such as infection by certain arthritogenic strains of B. burgdorferi,
retained spirochetal antigens (for example, peptidoglycans),
genetic risk factors, and evidence of prior joint trauma (43,
44). As in rheumatoid arthritis, the prototypical autoimmune
joint disease, Lyme arthritis is frequently accompanied by
autoimmune T- and B-cell responses to self-antigens (44).
These unresolved inflammatory and autoimmune responses may
contribute to ongoing arthritis, despite months of antibiotic
therapy. Consistent with this hypothesis, nearly all patients
with persistent Lyme arthritis experience resolution of arthritis
when treated with immunosuppressive drugs, including non-
steroidal anti-inflammatory drugs, corticosteroids, and other
antirheumatic drugs, such as methotrexate or tumor necrosis
factor-alpha inhibitors. Cellular analysis of the arthritic joint has
shown that large numbers of IFN-gamma-positive lymphocytes
are present in inflamed tissue and surrounding fluid (45).
Synovial fibroblasts, the most abundant cell type in synovial
tissue, show evidence of immune activation and express major
histocompatibility complex (MHC) class II molecules and other
immune factors associated with inflammation and lymphocyte
activation (44, 45).
Several self-peptides are immunogenic in Lyme disease
patients, so there seems to be a breakdown in immune tolerance
to self during B. burgdorferi infection. Autoimmune B cell
responses (but not T cell responses) can be detected early
in infection in patients with erythema migrans, but these
early autoimmune responses appear to be self-limiting and
non-pathogenic. T cell autoimmunity accompanies B cell
autoimmunity later in disease, such as during Lyme arthritis.
In late-stage disease, Lyme-disease-associated autoantibodies
correlate with clinical features of arthritis, suggesting that
autoimmunity in Lyme disease may become pathogenic
over time. Lyme arthritis progresses from early invasion
of synovial tissue to early inflammatory responses to later
inflammatory responses, and then to late tissue repair and
wound healing (44, 45). The role of infection as an autoimmune
trigger in Lyme disease is poorly understood, leading to the
following questions:
• What are the mechanisms by which B. burgdorferi infection
causes ongoing arthritic joint disease in a subset of patients?
• Are ongoing disease symptoms caused by the presence of
Borrelia antigens (such as peptidoglycans) rather than active
infection and, if so, why are they not cleared from the host?
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• Does Borrelia infection trigger autoimmune responses in
infected individuals and are these autoimmune responses
pathogenic in some patients?
Questions also remain regarding the role of immunosuppressive
treatments vs. differing antibiotic treatment regimens for
persistent Lyme arthritis, if peptidoglycan is an inflammatory
agent and persists despite 1–3 months of antibiotic therapy.
Patients who have persistent Lyme arthritis may represent
a different condition than do people with other Lyme
disease syndromes.
Whereas, prompt treatment of early Lyme disease, using
antibiotics with differing mechanisms of action, is usually
effective in prevention of persistence of B. burgdorferi and
persistent Lyme disease, similar antibiotic treatments for
persistent B. burgdorferi in animal models and in patients with
persistent Lyme disease appear to be ineffective. The reasons
for this difference are unclear, but may be due to a number of
possible mechanisms:
• The bacteria may be dormant or incapable of replication, yet
there may be the presence of residual antigens or the periodic
release of antigens, to which the host responds to produce the
symptoms associated with persistent Lyme disease.
• The bacteria may be entrenched in areas either inaccessible to
certain classes of antibiotics (for example, poorly vascularized
connective tissue, intracellular compartments), or higher
doses of antibiotics are needed to achieve levels that impede
metabolic activity.
• The bacteria may become antibiotic-tolerant, requiring
repeated courses of antibiotic treatment, combinations of
antibiotics, or periods of treatment alternating with periods of
no treatment.
There are indications that certain treatment regimens (for
example, tetracycline instead of doxycycline, the combination of
a macrolide antibiotic and an alkalinizing agent) are effective
in treating the persistent state if given over longer durations
of time rather than the usual 2–4-week periods. There is
ongoing research as well, some in the discovery phase, using
novel compounds to treat persisting organisms. There is
also some indication that the intestinal microbiota may play
an important role in the persistence or ability to eradicate
persisting organisms.
SUMMARY
The results of studies into the pathogenesis and pathophysiology
of Lyme disease, with the focus on the persistent state of the
causative organism, B. burgdorferi, have begun to elucidate the
mechanisms underlying the process by which the persistent state
occurs. However, important gaps exist into how the process
develops, from the organism’s existence in the Ixodes tick, to its
entry into the host, to its effects on the immune system, to its
distribution and ability to persist in certain tissues, to its ability to
persist despite innate and other host immune system responses,
and to its ability to persist despite certain antibiotic treatments.
But there is reason for optimism that additional research into
the pathogenetic and pathophysiologic mechanisms will lead to a
better understanding of the processes involved and ultimately to
a better means of preventing and treating patients with persistent
Lyme disease.
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